Diem Nguyen, Ph.D., serves as Chief Executive Officer and Director at SIGA Technologies Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies against infectious diseases and biological threats. Holding a Ph.D. in Biochemistry from the University of Montreal, Dr. Nguyen has amassed over 25 years of leadership experience in the biopharmaceutical sector, with a proven track record in vaccines, biologics, and global health security. Before joining SIGA in 2023, Dr. Nguyen was Chief Commercial and Innovation Officer at Emergent BioSolutions, where she drove commercial strategies, product launches, and innovation initiatives that significantly expanded revenue streams and market access for critical countermeasures. Her earlier career included senior roles at Sanofi Pasteur, leading vaccine development, regulatory approvals, and international commercialization efforts. Notable achievements include forging strategic partnerships, accelerating responses to pandemics, and advancing therapies that have protected millions from infectious diseases. At SIGA, Dr. Nguyen leads the company's strategic vision, overseeing the commercialization of its lead product, TPOXX® (tecovirimat), the only FDA-approved oral antiviral for smallpox, while advancing a robust pipeline against high-priority pathogens. Her expertise positions SIGA to address evolving biothreats, ensuring sustained delivery of life-saving solutions for governments and public health organizations worldwide.